Papers authored by Foos V

Collect these papers and discover other ones on Labmeeting. Learn more.
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
+ cite this
+ View Abstract
Tunis SL, Willis WD, and Foos V
Current medical research and opinion 26(1):163-75, 2010 Jan - Who cited this? | PubMed ID: 19919377 | Fulltext
Recommend
Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive.
+ cite this
+ View Abstract
Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, and Silberman C
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 12(1):1-9, 2009 Jan - Who cited this? | PubMed ID: 18657104 | Fulltext
Recommend
Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.
+ cite this
+ View Abstract
Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, and Palmer AJ
International journal of clinical practice 62(6):869, 2008 Jun - Who cited this? | PubMed ID: 18479280 | Fulltext
Recommend
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
+ cite this
+ View Abstract
Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M, and PROactive Study Group
Diabetic medicine : a journal of the British Diabetic Association 24(9):982-1002, 2007 Sep - Who cited this? | PubMed ID: 17593245 | Fulltext
Recommend
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
+ cite this
+ View Abstract
Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, Lammert M, and Roze S
Current medical research and opinion 23(4):895-901, 2007 Apr - Who cited this? | PubMed ID: 17407646 | Fulltext
Recommend
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
+ cite this
+ View Abstract
Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, and Palmer AJ
Current medical research and opinion 23(3):609-22, 2007 Mar - Who cited this? | PubMed ID: 17355742 | Fulltext
Recommend
Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
+ cite this
Currie CJ, McEwan P, Poole C, Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, and Roze S
Current medical research and opinion 22(5):967-9; author reply 968-9, 2006 May - Who cited this? | PubMed ID: 16709318 | Fulltext
Recommend
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
+ cite this
+ View Abstract
Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, and Roze S
Advances in therapy 23(2):191-207, 2006 - Who cited this? | PubMed ID: 16751153 | Fulltext
Recommend
CorrXpression--identification of significant groups of genes and experiments by means of correspondence analysis and ratio analysis.
+ cite this
+ View Abstract
Wessel R, Foos V, Aspelmeier A, Jürgens M, Graessmann A, and Klein A
In silico biology 6(1-2):61-70, 2006 - Who cited this? | PubMed ID: 16789914 | Fulltext
Recommend
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
+ cite this
+ View Abstract
Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, and Roze S
Current medical research and opinion 21(12):2063-71, 2005 Dec - Who cited this? | PubMed ID: 16368057 | Fulltext
Recommend
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States.
+ cite this
+ View Abstract
Minshall ME, Roze S, Palmer AJ, Valentine WJ, Foos V, Ray J, and Graham C
Clinical therapeutics 27(6):940-50, 2005 Jun - Who cited this? | PubMed ID: 16117994 | Fulltext
Recommend
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
+ cite this
+ View Abstract
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, and Spinas GA
Current medical research and opinion 20 Suppl 1:S5-26, 2004 Aug - Who cited this? | PubMed ID: 15324513 | Fulltext
Recommend
Validation of the CORE Diabetes Model against epidemiological and clinical studies.
+ cite this
+ View Abstract
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, and Spinas GA
Current medical research and opinion 20 Suppl 1:S27-40, 2004 Aug - Who cited this? | PubMed ID: 15324514 | Fulltext
Recommend



Search Google Scholar for Foos V

Join Labmeeting

  • Organize and search your PDF collection
  • Collect papers
  • Search millions of papers
  • Keep up to date with paper alerts
  • Read your papers from anywhere
  • Recommend papers to colleagues
  • Manage your lab
Sign Up

Join Labmeeting

Labmeeting is a web service for researchers. Sign up with your academic email address.

Individuals or corporations not affiliated with an academic institution can request a trial subscription.